advanced technologies

R&D

There are some 7,000 known rare diseases in the world, yet, multiple challenges and unmet needs remain when it comes to therapies for these diseases.

News

Eli Lilly's imlunestrant (Inluriyo) for breast cancer has received a new FDA approval, in combination with CDK4/6 inhibitor abemaciclib (Verzenio).

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.